The transcription factor T-cell acute lymphocytic leukemia (TAL)-1 is a major T-cell oncogene associated with poor prognosis in T-cell acute lymphoblastic leukemia (T-ALL). TAL1 binds histone deacetylase 1 and incubation with histone deacetylase inhibitors (HDACis) promotes apoptosis of leukemia cells obtained from TAL1 transgenic mice. Here, we show for the first time that TAL1 protein expression is strikingly downregulated upon histone deacetylase inhibition in T-ALL cells. This is due to decreased TAL1 gene transcription in cells with native TAL1 promoter, and due to impaired TAL1 mRNA translation in cells that harbor the TAL1 d microdeletion and consequently express TAL1 under the control of the SCL/ TAL1 interrupting locus (SIL) promoter. Notably, HDACi-triggered apoptosis of T-ALL cells is significantly reversed by TAL1 forced overexpression. Our results indicate that the HDACi-mediated apoptotic program in T-ALL cells is partially dependent on their capacity to downregulate TAL1 and provide support for the therapeutic use of HDACi in T-ALL.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is characterized by the clonal expansion of T-cell progenitors arrested at different stages of development. The T-cell acute lymphocytic leukemia (TAL)-1 transcription factor is essential for normal hematopoiesis. However, TAL1 expression is rapidly downregulated on commitment to the T-cell lineage.
1,2 Importantly, TAL1 is ectopically expressed in 65% of T-ALL patients. 3, 4 Aberrant expression of TAL1 in T-ALL results from relatively rare nonrandom translocations that include t(1;14)(p32;q11), t(1;7)(p32;q34), t(1;3)(p32;q21) and t(1;5)(p32;32), [5] [6] [7] [8] [9] and more frequently from a small interstitial deletion (del(1)p32 or Tal1 d ) that renders the TAL1 gene expression dependent on the upstream SCL/TAL1 interrupting locus (SIL) promoter. 10 Biallelic transcriptional activation, possibly resulting from deregulation of the machinery normally involved in TAL1 gene repression during normal T-cell development, can also account for TAL1 overexpression in some T-ALL cases, although the precise mechanism is still unknown. 11 The relevance of TAL1 in T-ALL is supported by studies reporting the development of fatal T-cell leukemia in TAL1 transgenic mice [12] [13] [14] [15] and showing that TAL1 expression in T-ALL cell lines is associated with protection from apoptosis. [16] [17] [18] Furthermore, TAL1 expression has been associated with poor prognosis in T-ALL. 4 Histone acetylation, which has a pivotal role in chromatin organization and gene expression, is mainly regulated by two complexes of enzymes. Histone acetyl transferases add acetyl groups to the N-terminus of histones, and histone deacetylases (HDACs) catalyze the opposite reaction. 19 Increased histone acetylation induces an open-chromatin conformation that allows the transcriptional machinery to access promoters and, in general, drives transcription. HDAC overexpression is commonly observed in cancer, 20 and HDAC inhibitors (HDACis) induce apoptosis and growth arrest in cancer cell lines. 19 Interestingly, gene expression profiling has shown that cancer cells treated with HDACis not only upregulate pro-apoptotic and growth-arrest genes but also commonly downregulate oncogenic and proliferative genes. 21, 22 TAL1 is a class II helix-loop-helix transcription factor that heterodimerizes with the class I transcription factors E2A, E2-2 and HEB [23] [24] [25] and binds to specific DNA sequences termed E-boxes. 26 In addition, TAL1 was shown to interact with HDAC1, 27 as well as with chromatin-remodeling complexes such as mSin3a 27 and HP1, 28 which influence TAL1 transcriptional activity. Moreover, TAL1 interaction with mSin3a has been observed in pre-leukemic thymocytes from TAL1 transgenic mice, and HDACi treatment was shown to selectively induce apoptosis of TAL1 transgenic leukemia cells without affecting TAL1-negative cells. 15 Given that HDACis were previously shown to decrease the expression of different oncogenes, [29] [30] [31] we speculated that TAL1 could be regulated by HDACs. We treated T-ALL cell lines and primary cells with sodium butyrate (SB) and suberoylanilide hydroxamic acid (SAHA) and found that TAL1 protein levels were strikingly reduced on treatment with these HDACis. This was due to inhibition of TAL1 gene transcription in leukemia cells with an intact TAL1 locus, and due to decreased protein translation in cells bearing the TAL1 d allele. Moreover, overexpression of TAL1 rescued HDACi-induced T-ALL cell apoptosis. Overall, these results indicate that HDACis target TAL1 expression in T-ALL, and suggest that the apoptotic effect of HDAC inhibition in T-ALL cells is partially dependent on TAL1 downregulation.
Materials and methods

T-ALL primary cells and cell lines
T-ALL patient samples were obtained from peripheral blood and/or bone marrow of patients with high leukemia involvement (85-100%). Informed consent and institutional review board approval was obtained for all sample collections in accordance with the Declaration of Helsinki. Samples were enriched by density centrifugation over Lympholyte (Cedarlane Laboratories, Hornby, Canada), washed twice in RPMI 1640 (Invitrogen) supplemented with 10% (vol/vol) FBS and 2 mM L-glutamine (hereafter referred to as RPMI10 medium), subjected to immunophenotypic analysis by flow cytometry as described previously. 32 The T-ALL cell lines CEM, Jurkat, PF382 and SupT1 were maintained in RPMI 10 medium and split every 2-3 days. T-ALL primary cells and cell lines were cultured at 37 1C with 5% CO 2 in RPMI 10 alone (with the appropriate vehicle when necessary), or in RPMI 10 plus the following: SB in the indicated concentrations (Sigma-Aldrich, Sintra, Portugal), 5 mM sodium phenyl butyrate (Biomol International, Plymouth, PA, USA), SAHA in the indicated concentrations (Cayman Chemicals, Montigny-le-Bretonneaux, France), 150 nM trichostatin A (Sigma-Aldrich), 2.5 mg/ml actinomycin D (Sigma-Aldrich), 500 mM cyclohexamide (Sigma-Aldrich) and 20 mM QVD-OPH (Biovision, Mountain View, CA, USA). At the indicated time points, the cells were harvested and processed as indicated below for assessment of cell viability, and RNA and protein extraction.
Transduction of T-ALL cells
PF382 cells were transduced with VSVG-pseudotyped TAL1-expressing lentiviruses. Briefly, 0.5 Â 10 6 cells were incubated in 500 ml RPMI10 and 500 ml of the corresponding lentiviral supernatant. The cells were then centrifuged for 2 h at 2000 r.p.m. at 33 1C, incubated overnight at 37 1C, washed and cultured in fresh medium. After expansion, cells were sorted for high green fluorescent protein expression. Viral supernatants were produced by transient transfection of 293 T cells, as described. 33 
Assessment of cell viability
Determination of cell viability was performed by flow cytometry analysis of forward scatter versus side scatter distribution using a FACScalibur (Becton-Dickinson, Mountain View, CA, USA). We have confirmed previously that this strategy measures lymphocyte viability as accurately as when using annexin V and propidium iodide staining. 32, 34 In experiments using primary T-ALL patient samples viable cells were counted by trypan-blue exclusion.
Immunobloting
Cell lysates were prepared as described 35 and equal amounts of protein were analyzed by 12% sodium dodecyl sulfatepolyacrylamide gel electrophoresis, transferred onto nitrocellulose membranes, and immunoblotted with the following antibodies or antiserum: Actin (Santa-Cruz Biotechnology, Santa Cruz, CA, USA); PARP (Novus Biologicals, Cambrigde, UK); phospho-S6 (S235/S236; Cell Signaling Technology, Danvers, MA, USA); P-Akt/PKB (S473; Cell Signaling Technology) and TAL1 (Millipore, Temecula, CA, USA). Where indicated, densitometry analysis was performed using Adobe Photoshop CS3 software (version 10.0, Adobe Systems Incorporated, San Jose, CA, USA). Each band was analyzed with a constant frame and normalized to the respective loading control.
RNA extraction, reverse transcription-PCR and quantitative-reverse transcription-PCR
Where indicated, RNA was extracted using a High Pure Isolation Kit (Roche Diagnostics, Indianapolis, IN, USA) according to the manufacturer's instructions. For the reverse transcription-PCR, up to 1 mg of total RNA was reverse transcribed using SuperScript II (Invitrogen) and random hexamers. Expression of each gene was normalized to the expression levels of glyceraldehyde 3-phosphate dehydrogenase, 18S or ABL as indicated. Primers used for the quantitativereverse transcription-PCR are indicated in Supplementary Table  S1 . The transcripts were amplified in 25 ml reactions, using 10 ml cDNA, 12.5 ml Power SYBR Green (Applied Biosystems, Foster City, CA, USA) and 200 nM of each primer, according to the manufacturer's instructions. All the amplifications were performed in an ABI PRISM 7500 thermocycler (Applied Biosystems) for 2 min at 50 1C, 10 min at 95 1C, followed by 45 cycles of 15 s at 95 1C, and 1 min at 60 1C.
Chromatin immunoprecipitation
For chromatin immunoprecipitation, 2 Â 10 8 Jurkat cells were used for each condition. Cells were washed twice in 1 Â phosphate buffered saline and crosslinked with 1% formaldehyde at room temperature. Cells were then lysed in sodium dodecyl sulfate lysis buffer and sonicated. Chromatin was precleared for 1 h at 4 1C using protein A-sepharose beads and then incubated overnight with 5 mg rabbit polyclonal antibody against RNA polymerase II (Santa Cruz Biotechnology) and H3K9Ac (histone H3 lysine-9 acetylation; Abcam, Cambrigde, UK). DNA-protein complexes were pulled down with protein A-sepharose beads (Sigma-Aldrich) for 4 h at 4 1C, washed, and eluted in 1% sodium dodecyl sulfate and 0.1 M NaHCO 3 elution buffer. Crosslink was reversed overnight at 65 1C in 0.2 M NaCl (the input samples were also reverse crosslinked). DNA was purified using phenol:chloroform extraction and ethanol precipitation, eluted in DNase/RNase-free water and used for quantitative-reverse transcription-PCR analysis. Primers were designed to amplify specific regions of the TAL1 gene and are indicated in Supplementary Table S2 .
Statistical analysis
Differences between populations were calculated using unpaired two-tailed Student's t-test or one-way analysis of variance, as appropriate (Po0.05 was considered significant).
Results
HDAC inhibition downregulates TAL1 protein levels in T-ALL cells
HDACis are potent inducers of apoptosis in T-cell tumors derived from TAL1 transgenic mice. 15 As TAL1 has been implicated in prevention of T-ALL cell apoptosis, [16] [17] [18] we hypothesized that TAL1 expression and/or activity could be altered by treatment with HDACi. To answer this question, we treated several T-ALL cell lines with the HDACi SB. TAL1 protein expression decreased significantly in all the cell lines tested (Figures 1a and b) . Similar results were obtained with other HDACis, including sodium phenyl butyrate, trichostatin A and SAHA (Figure 1b) . Moreover, the negative effect of HDACi on TAL1 protein expression was time (Figures 1c and d) and dose (Figures 1e and f) dependent.
HDACi-mediated TAL1 protein downregulation in T-ALL cells is not due to increased apoptosis or protein degradation
HDACis were shown to induce apoptosis of acute lymphoblastic leukemia cell lines, including T-ALL. 36 Analysis of PARP Several reports indicate that HDACis affect protein stability, inducing degradation of oncogenes and cellular proteins. 29, 37 To test whether protein degradation has a role in the TAL1 protein downregulation induced by HDACi, we treated Jurkat cells (Figure 2e ) with the protein translation inhibitor cycloheximide. The half-life of TAL1 protein, which is roughly 6 h in Jurkat cells, is not significantly altered by treatment with SB (Figure 2f ), indicating that HDACis do not have a major effect on TAL1 protein stability. Similar results were obtained in PF382 cells on treatment with cycloheximide and SB, although TAL1 protein half-life was significantly longer in these cells (around 12-16 h; data not shown).
HDAC inhibition downregulates TAL1 transcript levels without affecting TAL1 splicing or mRNA stability
HDACis have been reported to diminish the transcript levels of specific genes by inhibiting gene transcription 31 and by decreasing mRNA stability. 30, 38 Hence, we next evaluated whether HDACis decreased TAL1 protein expression in T-ALL cells through downregulation of TAL1 mRNA levels. Treatment of Jurkat and SupT1 cells with SB and SAHA for 24 h induced a dramatic downregulation of TAL1 mRNA levels (Figure 3a) . Similar results were obtained using three primary leukemia samples collected from T-ALL patients at diagnosis (Figure 3b) . Moreover, downregulation of TAL1 mRNA levels was rapid (Figures 3c and d) and dose dependent (Figures 3e and f) . Notably, the decrease in TAL1 mRNA was not due to increased apoptosis (Supplementary Figure S1 ) or due to a generalized negative effect on gene expression, as HDACi treatment clearly upregulated the transcript levels of CDKN1A, the gene coding for the cell cycle inhibitor p21 CIP1 (Supplementary Figure S2 ), in accordance with previous reports. 39, 40 Given the rapid downregulation of TAL1 transcript levels and the fact that the TAL1 gene is composed of several exons (Supplementary Figure S3a) , we hypothesized that TAL1 splicing was impaired upon HDAC inhibition, leading to an accumulation of unspliced RNA that would result in decreased detection of the processed TAL1 mRNA. To address this possibility, we treated Jurkat cells for up to 6 h with 5 mM SB. No difference between the levels of total and processed TAL1 transcripts was observed at any of the time points analyzed (Figure 3g ), suggesting that HDACi treatment did not affect TAL1 mRNA splicing.
Several lines of evidence indicate that HDACi may decrease mRNA stability. 30, 38 To test whether this could be the cause for decreased TAL1 mRNA expression, we treated Jurkat cells with actinomycin D, a known inhibitor of gene transcription. We treated Jurkat cells with 5 mM SB, 2.5 mg/ml actinomycin D or the combination of both inhibitors for 6 h and analyzed TAL1 mRNA levels. Treatment with actinomycin D decreased TAL1 mRNA similarly to SB, and the combination of both did not further downregulate TAL1 transcript levels (Figure 3h ). These data suggest that HDACi treatment did not affect TAL1 mRNA stability. 
HDAC inhibition abrogates TAL1 transcription in TAL1-positive T-ALL cells with an intact TAL1 locus
Because neither mRNA splicing nor stability was significantly affected by HDAC inhibition, we next asked whether HDACis could directly affect TAL1 gene transcription. We treated Jurkat cells with 5 mM SB for 4 h and performed chromatin immunoprecipitation to analyze the binding of RNA polymerase II and the levels of histone H3 lysine-9 acetylation, which is a marker of actively transcribed euchromatin. 41 SB incubation abrogated the binding of RNA polymerase II to the TAL1 promoter 1a and to exon 4 ( Figure 3i ). It is interesting to note that TAL1 exon 4 had a higher binding toward RNA polymerase II than the promoter 1a in the control condition (Figure 3i) , suggesting that the TAL1 promoter IV 42 located within this exon is active. Notably, SB incubation substantially decreased histone H3 lysine-9 acetylation, both at TAL1 promoter 1a and at exon 4 ( Figure 3j ). Altogether, these results clearly indicate that HDACis actively reduce binding of RNA polymerase II to TAL1 promoters and inhibit TAL1 gene transcription.
HDAC inhibition upregulates TAL1 transcripts in T-ALL cells with TAL1 d
As shown above, cell lines with an intact TAL1 locus (hereafter referred to as TAL1 wt ), such as Jurkat and SupT1, downregulated TAL1 protein levels after HDACi treatment, due to decreased TAL1 mRNA levels that resulted from diminished gene transcription. However, we found that other T-ALL cell lines, such as PF382 and CEM, paradoxically upregulated TAL1 transcript levels on incubation with HDACi (Figure 4a ), despite the fact that TAL1 protein expression was clearly decreased by all the HDACis tested (Figures 1a and b) . We speculated that this could be due to the fact that TAL1 gene expression is not driven by its native promoters in these cell lines, in such a way that HDACi treatment would not negatively affect TAL1 transcription. Similar to primary patient samples, some TAL1 Figure S4a) . Using primers that specifically detect SIL-TAL1 fusion transcripts, 43 we confirmed that PF382 cells (Supplementary Figure S4b A recent report showed that SAHA inhibits cyclin D1 translation. 44 Therefore, we speculated that HDACi impaired TAL1 protein translation in TAL1 d cells and thereby negatively regulated TAL1 protein levels. To test this hypothesis, we pretreated PF382 cells for 6 h with cycloheximide, and then removed the translation inhibitor to allow de novo protein synthesis. SB was incubated for additional 24 h to analyze its effect on de novo translation of TAL1. Incubation with SB inhibited TAL1 protein translation (Figure 4c ), suggesting that HDAC inhibition impaired TAL1 protein translation in TAL1 d cell lines.
Forced TAL1 expression partially rescues T-ALL cell death induced by HDAC inhibition
HDACis were shown to induce apoptosis in human leukemia cell lines 36, 45 and primary cells. 46 In accordance, we observed that primary T-ALL samples (Supplementary Figure S5a) and cell lines (Supplementary Figure S5b) when treated with different HDACis entered apoptosis. TAL1 expression was shown to prevent apoptosis of T-ALL cells, 16, 17 and HDACis were reported to promote cell death of TAL1-expressing mouse leukemia cells. 15 Thus, we next compared the efficacy of HDAC inhibition upon forced expression of TAL1 in T-ALL cells. We transduced PF382 (Figure 5a ) and Jurkat (Supplementary Figure S6) cells with a lentiviral vector driving the expression of TAL1. Forced expression of TAL1 significantly reversed T-ALL cell death induced by treatment with SB ( Figure 5 and Supplementary Figure S6) . These results suggest that HDACis promote apoptosis of T-ALL cells in part via downregulation of TAL1.
Discussion
HDACis affect global gene expression. In cancer cells, HDACis have been shown to induce the transcription of genes associated with apoptosis and cell-cycle arrest, while decreasing the expression of oncogenes and genes that promote proliferation. 21, 22, [29] [30] [31] Here, we showed for the first time that TAL1, a major T-cell oncogene, was strikingly downregulated in T-ALL cells on treatment with HDACis and that TAL1 forced expression partially reversed the pro-apoptotic effect of HDACis on the leukemic cells.
TAL1 ectopic expression in T-ALL cells can result from different nonrandom chromosomal translocations [5] [6] [7] [8] [9] that, for example, juxtapose the promoter region of TCR genes to the TAL1 locus. More frequently, TAL1 is expressed because of a small interstitial deletion (TAL1 d ) that places TAL1 under the control of the regulatory elements of the SIL locus. 10 In both instances, TAL1 overexpression results from the presence of a non-native 'TAL1 promoter' that aberrantly drives TAL1 transcription. In most cases, however, TAL1 ectopic expression results from other, as yet unknown, mechanisms that apparently do not involve genomic alterations in the TAL1 locus (TAL1 wt ). In these cases TAL1 expression is aberrantly promoted by native regulatory elements, perhaps due to epigenetic alterations affecting the chromatin structure. Our present studies indicate that HDACis negatively affected TAL1 gene transcription in TAL1 wt T-ALL cells by suppressing the binding of RNA polymerase II to the TAL1 promoter(s). In contrast, HDACis upregulated TAL1 mRNA levels in TAL1 d cells (Supplementary Figure S7) . This discrepancy likely reflects differences in the respective promoters and their regulation. Normal T-cell precursors do not express TAL1, which suggests that TAL1 ectopic expression in TAL1 wt cells results from an aberrantly accessible TAL1 locus and/or from the inhibition of negative regulators of TAL1 transcription. It is possible that HDACs have been selected by T-ALL cells to partake in this process. In this regard, it is noteworthy that the transcripts of HDAC1 and HDAC4 were recently shown to be highly expressed in primary T-ALL patient samples. 47 Whether HDAC1 and HDAC4 positively regulate TAL1 gene transcription in T-ALL cells Actin was used as a loading control. TAL1 protein levels were quantified by densitometry analysis, normalized to actin and depicted as relative values to the medium control condition at 6 h of treatment. (c) PF382 cells were incubated for 6 h with 500 mM cyclohexamide, washed and then treated for further 24 h with 5 mM SB. Cells were lysed at the indicated time points that represent the time point when SB was added to the cells. TAL1 expression was analyzed by immunoblot and actin was used as a loading control. TAL1 protein levels were quantified by densitometry analysis, normalized to actin and depicted as relative values to the medium control condition at 6 h of treatment. The data are representative of at least three independent experiments. warrants investigation. HDACis can also induce the acetylation of proteins other than histones. 48 Thus, one can picture at least two mechanisms by which HDACis can downregulate TAL1 gene transcription: histone acetylation nearby the promoter of a negative regulator of TAL1 gene expression (with consequent increase in its transcription) and/or direct acetylation and functional activation of the TAL1 repressor. Whatever the mechanism, HDACis downregulate TAL1 mRNA expression in TAL1
wt similarly to what has been frequently reported for other oncogenes. 30, 31, 49 In TAL1 d T-ALL cells, TAL1 is under the control of the SIL promoter that is normally active in hematopoietic cells. 50 In this scenario, it is not surprising that HDACis act by inducing an openchromatin conformation that further activates TAL1 transcription.
TAL1 protein levels decreased on treatment with HDACis in both TAL1 wt and TAL1 d cells, indicating the existence of an additional mechanism of regulation that counterbalances increased TAL1 mRNA expression in the latter. Indeed, we found that HDACis impair TAL1 translation, leading to a slow but significant decrease in TAL1 protein levels (Supplementary Figure S7) . It is probable that HDACis have the potential to inhibit TAL1 translation also in TAL1 wt T-ALL cells, although the rapid shutdown of TAL1 gene transcription in these cells renders this mechanism irrelevant or vestigial. It has been shown that treatment of mantle cell lymphoma cells with SAHA abrogates cyclin D1 translation by direct inhibition of phosphatidylinositol 3-kinase activity. 44 However, inhibition of phosphatidylinositol 3-kinase or its downstream target mTOR does not mimic the effect of HDACi on TAL1 protein expression (Supplementary Figure S8) , suggesting that a different pathway controls TAL1 translation in T-ALL.
In summary, we showed that HDACis promote human T-ALL cell death at least in part via a previously unrecognized mechanism involving downregulation of TAL1 expression. Because TAL1 is one of the most commonly deregulated oncogenes in T-ALL, defining a major cytogenetic subgroup with bad prognosis, our data provide further rationale for the inclusion of HDACi into T-ALL therapeutic regimens.
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